

**REFERENCES**

1. Maron BJ, Ommen SR, Semsarian C, et al. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. *J Am Coll Cardiol* 2014;64:83-99.
2. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. *J Am Coll Cardiol* 2008;52:686-717.
3. Eleid MF, Konecny T, Orban M, et al. High prevalence of abnormal nocturnal oximetry in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2009;54:1805-9.
4. Sengupta PP, Sorajja D, Eleid MF, et al. Hypertrophic obstructive cardiomyopathy and sleep-disordered breathing: an unfavorable combination. *Nat Clin Pract Cardiovasc Med* 2009;6:14-5.
5. Bitter T, Westerheide N, Prinz C, et al. Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. *Eur Heart J* 2011;32:61-74.

**REPLY: Obstructive Sleep Apnea and Hypertrophic Cardiomyopathy**



Obiter Dictum or More?

We greatly appreciate the positive comments offered by Drs. Jan and Tajik regarding our contemporary review of diagnostic and management strategies for hypertrophic cardiomyopathy (HCM) (1). However, Drs. Jan and Tajik point out that we have ignored the role of obstructive sleep apnea (OSA) in the clinical course of patients with HCM. On reflection, we agree that it was perhaps an oversight not to at least mention OSA, given the increasing data suggesting that OSA may contribute to drug-refractory symptoms and left ventricular outflow gradients in this disease (2,3). On the other hand, we believe that it is probably premature to consider OSA to be a sudden death risk stratification marker

in HCM, given the limited observational data that are currently available. Nevertheless, because the HCM risk factor algorithm remains incomplete (4,5), additional relevant variables would represent a significant contribution to disease management. Given its influence on clinical outcomes in a variety of cardiovascular diseases, OSA warrants further investigation in this regard.

\*Barry J. Maron, MD  
Steve R. Ommen, MD  
Christopher Semsarian, MBBS, PhD  
Paolo Spirito, MD  
Iacopo Olivetto, MD  
Martin S. Maron, MD

\*Hypertrophic Cardiomyopathy Center  
Minneapolis Heart Institute Foundation  
920 East 28th Street, Suite 620  
Minneapolis, Minnesota 55407  
E-mail: [hcm.maron@mhif.org](mailto:hcm.maron@mhif.org)  
<http://dx.doi.org/10.1016/j.jacc.2014.10.001>

**REFERENCES**

1. Maron BJ, Ommen SR, Semsarian C, et al. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. *J Am Coll Cardiol* 2014;64:83-99.
2. Eleid MF, Konecny T, Orban M, et al. High prevalence of abnormal nocturnal oximetry in patients with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 2009;54:1805-9.
3. Sengupta PP, Sorajja D, Eleid MF, et al. Hypertrophic obstructive cardiomyopathy and sleep disordered breathing: an unfavorable combination. *Nat Clin Pract Cardiovasc Med* 2009;6:14-5.
4. Spirito P, Autore C, Formisano F, et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. *Am J Cardiol* 2014;113:1550-5.
5. Chan RH, Maron BJ, Olivetto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. *Circulation* 2014;130:484-95.